A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia.

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PEARL
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2016 Results of a post hoc analysis of data from this trial will be presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), according to a Sunovion Pharmaceuticals media release.
    • 28 Jan 2014 New source identified and integrated (EudraCT record: 2011-001711-31).
    • 27 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT01435928).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top